Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities

Significance A substantial portion of cancer patients treated by immune checkpoint (IC) therapy develop immune-related adverse events (irAEs), which result in significant morbidity and mortality. We sought to understand the mechanisms of these irAEs and to identify biomarkers to predict irAEs to maximize the clinical benefits of IC therapy. We screened plasma samples from patients who developed IC therapy-induced hypophysitis or pneumonitis...